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Do regional brain volumes and major depressive disorder
share genetic architecture? A study of Generation Scotland
(n= 19762), UK Biobank (n= 24048) and the English
Longitudinal Study of Ageing (n= 5766)
EM Wigmore1, T-K Clarke1, DM Howard1, MJ Adams1, LS Hall1, Y Zeng1, J Gibson1, G Davies2, AM Fernandez-Pujals1, PA Thomson2,3,
C Hayward3, BH Smith4, LJ Hocking5, S Padmanabhan6, IJ Deary2,7, DJ Porteous3, KK Nicodemus2,3 and AM McIntosh1,2
Major depressive disorder (MDD) is a heritable and highly debilitating condition. It is commonly associated with subcortical
volumetric abnormalities, the most replicated of these being reduced hippocampal volume. Using the most recent published data
from Enhancing Neuroimaging Genetics through Meta-analysis (ENIGMA) consortium’s genome-wide association study of regional
brain volume, we sought to test whether there is shared genetic architecture between seven subcortical brain volumes and
intracranial volume (ICV) and MDD. We explored this using linkage disequilibrium score regression, polygenic risk scoring (PRS)
techniques, Mendelian randomisation (MR) analysis and BUHMBOX. Utilising summary statistics from ENIGMA and Psychiatric
Genomics Consortium, we demonstrated that hippocampal volume was positively genetically correlated with MDD (rG = 0.46,
P= 0.02), although this did not survive multiple comparison testing. None of the other six brain regions studied were genetically
correlated and amygdala volume heritability was too low for analysis. Using PRS analysis, no regional volumetric PRS demonstrated
a signiﬁcant association with MDD or recurrent MDD. MR analysis in hippocampal volume and MDD identiﬁed no causal association,
however, BUHMBOX analysis identiﬁed genetic subgrouping in GS:SFHS MDD cases only (P= 0.00281). In this study, we provide
some evidence that hippocampal volume and MDD may share genetic architecture in a subgroup of individuals, albeit the genetic
correlation did not survive multiple testing correction and genetic subgroup heterogeneity was not replicated. In contrast, we
found no evidence to support a shared genetic architecture between MDD and other regional subcortical volumes or ICV.
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INTRODUCTION
Major depressive disorder (MDD) is a debilitating condition that
accounts for a large proportion of disease burden world-wide.1 It
is a complex disorder that is inﬂuenced by both genetic and
environmental factors with a heritability of ~ 37% estimated from
twin studies.2 Two recent genome-wide association studies
(GWAS) identiﬁed two loci in MDD3 and 15 loci in self-reported
depression4 of genome-wide signiﬁcance. Nevertheless, the
majority of MDD’s heritability is unaccounted for by currently
identiﬁed variants and the mechanisms leading from gene to
clinical phenotype remain elusive.
Reports of lower brain volumes in cross-sectional studies are
common in MDD, but small sample sizes have potentially
contributed to poorly replicated results. Enhancing Neuro-
Imaging Genetics through Meta-Analysis (ENIGMA) completed a
large MDD case–control meta-analysis of subcortical volumes
(n= 8927) demonstrating a signiﬁcant association between MDD
and reduced hippocampal volume (Cohen’s d=− 0.20).5 Numer-
ous other studies have also demonstrated a link between
hippocampal reduction and MDD, and it is one of the most
robustly associated brain regions.6 Other brain regions have
shown limited and sometimes contradictory evidence for associa-
tion with MDD. Smaller amygdala volume has been associated
with depressive symptoms7,8 and MDD status,9 however larger
amygdala volume has also been associated with the disorder.10 A
2013 meta-analysis concluded that, as well as hippocampus,
smaller putamen and thalamus volumes were associated with late
life MDD, although fewer studies have examined these regions.11
In addition, smaller caudate nucleus volumes have also been
associated with MDD in a meta-analysis.12 The nucleus accumbens
has not been widely associated with MDD status but a smaller
volume has been implicated in the lethality of suicidal acts within
mood disorder sufferers.13 Pallidum volume and intracranial
volume (ICV) have not been associated with MDD in any meta-
analysis to date, as far as we are aware.
Subcortical structural volumes are known to be inﬂuenced by
both genetic and environmental factors and have been demon-
strated to be moderately to highly heritable ranging from 0.44 to
0.88.14 The previously reported lower brain volumes in MDD and
the relatively high heritability of these structures means they
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could be of interest as an intermediate phenotype.14 Overlap
between genes involved in MDD and subcortical regions have
been explored previously. The majority of studies have focused on
candidate genes, such as the serotonin transporter (5-HTTLPR),
and ﬁndings have often been contradictory.15 As the success of a
candidate gene study is reliant on the correct gene being chosen,
GWAS studies are often considered to be a less biased and more
reliable approach.16 GWAS of regional brain volumes has recently
been completed by the ENIGMA Consortium,17 providing an
important opportunity to examine the genetic overlap between
subcortical brain volumes and ICV with MDD. Indications of
covariation could potentially identify the risk conferring loci
involved in MDD as well as the underlying mechanisms.
In this current study, we examine whether the genetic
architecture of MDD is shared with multiple subcortical brain
regions and ICV. We employed four techniques; the ﬁrst, linkage
disequilibrium (LD) score regression,18,19 estimates the genetic
correlation between these traits using GWAS summary statistics
from the ENIGMA consortium and Psychiatric Genomics Con-
sortium (PGC). The second method, polygenic risk scoring (PRS),20
utilises ENIGMA summary statistics to generate individual level
polygenic proﬁle scores of each brain region’s volume. We then
calculated the association of PRS (a) with their own volume in UK
Biobank and (b) with MDD status in three population-based
cohorts; Generation Scotland: Scottish Family Health Study (GS:
SFHS), English Longitudinal Study of Ageing (ELSA) and UK
Biobank and (c) with recurrent MDD, MDD episodes, MDD
duration and age of onset in GS:SFHS and UK Biobank. Both (b)
and (c) analyses were adjusted for confounds on an individual
subject level and then combined in a meta-analysis. Third, we
used the Mendelian randomisation method21 to examine a
directional causal relationship between the regional volumes
and MDD, utilising the GWAS signiﬁcant loci as genetic instru-
ments. Lastly, we used a new software package BUHMBOX22 to
test for the presence of genetic subgroup heterogeneity.
MATERIALS AND METHODS
Cohort descriptions and genotyping
Generation Scotland: Scottish Family Health Study. GS:SFHS is a family-
based cohort with phenotypic data for 24 080 participants (mean
age= 47.6, s.d. = 15.4) of which 20 032 had genotype data. Individuals
were eligible if they had one ﬁrst-degree relative willing to partake in the
study. Further details on the recruitment for this cohort are available in the
Supplementary Materials and have been described previously.23 Diagnosis
of MDD was made using the structured clinical interview for DSM-IV
disorders (SCID) for those individuals that screened positive during
interview questions (n= 19 762, cases = 2643).24 Individuals with bipolar
disorder (n= 76) were excluded from this study. Information on MDD
episodes and age of onset was also included in the SCID and therefore
recurrent MDD and duration of MDD could be inferred (further details are
given in the Supplementary Materials).
Details of the DNA extraction for GS:SFHS have been previously
described.25 Genotyping was completed at the Wellcome Trust Clinical
Research Facility Genetics Core, Edinburgh (www.wtcrf.ed.ac.uk) using the
Illumina HumanOmniExpressExome -8v1.0 Beadchip (San Diego, CA, USA)
and Inﬁnium chemistry26 and processed using GenomeStudio Analysis
Software v2011.1. Quality Control (QC) utilised the following inclusion
thresholds; missingness per individual o1%, missingness per single-
nucleotide polymorphism (SNP) o1%, Hardy–Weinberg Equilibrium (HWE)
P-value 41× 10− 6, minor allele frequency (MAF) 41%. There were
556 705 SNPs and 19 994 individuals that passed QC criteria.
UK Biobank. UK Biobank is an open resource cohort with phenotypic data
for 502 664 (mean age= 56.5, s.d. = 8.1) between the ages of 40–69
recruited within the United Kingdom between 2006 and 2010, with
genotype data available for 152 734 participants. Our study was conducted
under UK Biobank application 4844. Study design and recruitment has
been described previously27 but, in brief, participants were asked to
complete a touchscreen questionnaire and additional data were collected
by nurse interview. MDD status was based upon putative MDD phenotype
deﬁned by Smith et al.28 (n= 24 048). Participants with mild depressive
symptoms were removed based on this deﬁnition and self-reported
bipolar disorder participants (n= 1211) were excluded. Information on
MDD episodes and age of onset was also available, therefore recurrent
MDD and MDD duration was inferred (further details are given in the
Supplementary Materials). Subcortical volumes for nucleus accumbens,
amygdala, caudate nucleus, hippocampus, pallidum, putamen and
thalamus were measured by T1-weighted structural imaging. The UK
Biobank imaging protocol has been described elsewhere (http://biobank.
ctsu.ox.ac.uk/crystal/refer.cgi?id = 1977). The mean of the sum of left and
right volume was taken for each subcortical region. ICV was generated by
the sum of white matter, grey matter and ventricular cerebrospinal ﬂuid
volumes. Imaging data for the eight structures were available for 4446
participants, of which 968 had genetic data available.
Genotyping was completed utilising two Affymetrix arrays (Santa Clara,
CA, USA); BiLEVE (n=49 979) and the UK Biobank Axiom (n= 102 750).
Details have been described previously.29 Initial genotyping QC was
performed by UK Biobank.30 Additional ﬁltering was then applied to
participants with poor heterozygosity or missingness, QC failure, non-
British White ancestry, gender mismatch, genotype missingness o2%, and
relatedness within UK Biobank and to the GS:SFHS sample (r40.0442,
n= 35 752) and ELSA sample (in the meta-analysis with all three cohorts).
SNPs inclusion criteria were HWE P41 × 10− 6 and MAF41%. There were
731 536 SNPs and 152 735 individuals that passed QC criteria.
English Longitudinal Study of Ageing. ELSA is a prospective cohort study of
health and ageing collected in 2002 with six follow-up waves taken at 2-
year intervals. At wave 1 (baseline), phenotypic data were available for
12 003 (mean age= 63.9, s.d. = 10.7) and genotypic data available for 7452
participants. Details of this cohort have been described previously31 and
further information is available in the Supplementary Materials. MDD status
in this study was deﬁned using a shortened form of the Centre of
Epidemiological Studies—Depression scale (CES-D scale) (completed by
5752 participants with genomic data). This consisted of 8 questions, rather
than the original 20, with a ‘no’/‘yes’ response that was converted to a
binary 0/1, respectively, although positive questions, that is, ‘During the
past week, were you happy?’, were scored in reverse; 0 being ‘yes’ and 1
being ‘no’. After summing the scores, a dummy variable of MDD status was
classiﬁed as those with a score of 4 or above, as in previous studies.32 Self-
reported ‘manic depressive’ (n= 41) individuals were excluded.
Genotyping was completed in 2013/14 on 7452 participants on the
Illumina Omni 2.5–8 chip and QC and removal of related individuals
(r≥ 0.2, n= 109) was completed at the University College London Genetics
Institute. Further QC was implemented using the same inclusion thresholds
as used for GS:SFHS; SNP inclusion criteria were HWE P41× 10− 6 and
MAF41% and exclusion of related individuals (r4=0.2, n=109). There
were 41.3 million SNPs and 7230 individuals that passed QC criteria.
LD score regression
Genetic correlation of subcortical structures and ICV with MDD were
measured using the LD score regression technique.18,19 In brief, this
technique utilises GWAS summary statistics to estimate the SNP-based
heritability of a trait and genetic correlation between traits, in this study we
used summary data from ENIGMA and PGC. SNPs inclusion criteria were
INFO40.9 and MAF4%1 (further details in Supplementary Materials).
Summary statistics for the regional brain volume GWAS completed by
ENIGMA were downloaded from http://enigma.ini.usc.edu/research/down
load-enigma-gwas-results/. The GWAS was completed using 11 840
participants for eight MRI volumetric measures; nucleus accumbens,
amygdala, caudate nucleus, hippocampus, pallidum, putamen, thalamus
and ICV.17
Summary statistics for the MDD GWAS completed by the MDD Working
Group of the PGC were downloaded from http://www.med.unc.edu/pgc/
downloads. The study examined 9238 MDD cases and 8039 controls.33
Polygenic risk scoring
Construction of PRS was completed in PLINK software.34 PRS utilise effect
sizes from GWAS summary statistics to construct an additive individual
genetic scores in a population.20 Summary statistics were taken from
the ENIGMA GWAS17 (details above) to construct weighted PRS using ﬁve
P-value thresholds: 0.01, 0.05, 0.1, 0.5 and 1, after SNPs underwent
clumped-based pruning (r2 = 0.25, 300 kb window). All ﬁve thresholds are
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reported in models of subcortical volume and ICV PRS predicting their
respective volume in UK Biobank and the best predictive threshold was
carried forward into models associating MDD status with each subcortical
volume and ICV in all three cohorts. The P-value thresholds carried forward
were; nucleus accumbens: 0.01, amygdala: 0.1, caudate nucleus: 0.5,
hippocampus: 0.01, ICV: 0.5, pallidum: 0.5, putamen: 0.1 and thalamus: 0.05.
Scores for GS:SFHS, UK Biobank and ELSA were computed on the raw
genotypes.
Statistical analysis
Association between regional brain volume PRS and its respective volume.
Models predicting regional brain volumes in UK Biobank were conducted
using linear regression in R version 3.2.3 (www.r-project.org). Models were
adjusted for age, sex and the ﬁrst 15 principal components (PCs) as well as
for ICV (excepting ICV itself).
Association between regional brain volume PRS and MDD. Mixed linear
model analyses were completed in ASReml-R (http://www.vsni.co.uk/
software/asreml/) for GS:SFHS with MDD status. Mixed linear modelling
was utilised to account for the family structure in GS:SFHS. MDD status was
ﬁtted as the dependent variable and volume PRS ﬁtted as the independent
variable. The model was adjusted for age and sex with the ﬁrst four PCs
ﬁtted to control for population stratiﬁcation. An additive relationship
matrix (expected relatedness derived from pedigree information) was
ﬁtted as a random effect to account for the family structure in GS:SFHS.
Wald’s conditional F-test was used to calculate P-values for all ﬁxed effects
and the variance explained was calculated by division of the difference in
the sum of residual variance and additive genetic effect in the null model
(without PRS) with the full model (with PRS). To adjust for the use of linear-
mixed regression models being applied to a binary dependent variable in a
structured data set, the ﬁxed effects and standard errors from the linear
model were transformed utilising a Taylor series approximation35 from the
linear scale to the liability scale (Supplementary Materials).
In unrelated samples (UK Biobank and ELSA) logistic regression utilising
generalised linear models in R version 3.2.3 (www.r-project.org) was used
to test the degree of association between MDD and PRS of subcortical
volumes and ICV. Models were adjusted for age, sex and the ﬁrst 15 PCs (in
UK Biobank) and ﬁrst 4 PCs (in ELSA) to control for varying levels of
population stratiﬁcation present in the samples.
Association between hippocampus volume PRS and MDD traits. As
hippocampal volumetric differences have been more closely associated
with recurrent MDD and early illness onset,5,36 hippocampus PRS
regression analyses were also run with recurrent MDD, number of
episodes, MDD duration and age of onset as dependent variables (for
further details see Supplementary Materials). In GS:SFHS these were run
utilising mixed linear model analysis (as above) to account for the family
structure. As recurrent MDD is a binary trait, this was transformed from the
linear to liability scale using the Taylor series approximation35 (as above).
For testing association in unrelated samples, logistic regression models
were used for binary traits (recurrent MDD) and linear regression for
quantitative traits (number of episodes, MDD duration and age of onset).
Models were adjusted for age, sex and the ﬁrst 15 PCs to control for
population stratiﬁcation. These data were not available for ELSA therefore
this was run in UK Biobank only.
Meta-analysis. In order to increase power, ﬁxed effect meta-analysis,
weighted by standard error of the beta values relating PRS scores to MDD
was carried out using the ‘meta’ package (version 4.3-2)37 in R.
Mendelian randomisation
Mendelian randomisation (MR) is an approach that examines genetic
variants in association with an exposure and outcome to determine
causality. In this study if a signiﬁcant genetic correlation (Po0.05) was
found (indicating pleiotropy) it was carried forward into a two-sample MR
analysis. We utilised the ‘MendelianRandomization’ package (v0.2.0) in R to
conduct both an Inverse-Variance Weighted (IVW) analysis and MR-Egger
regression.21 In brief, the IVW method incorporates multiple SNPs as a
vector of instrumental variables (IVs) and carries out weighted linear
regression analysis between the IVs vector—outcome and IVs vector—
exposure. The analysis is weighted on the inverse variance of the IVs vector
—outcome association and the intercept constrained to zero. We utilised
the effect beta from the genome-wide signiﬁcant variants from the original
ENIGMA GWAS as the association between variants and exposure and the
effect beta from the same variants in the PGC GWAS as the association
between the variant and outcome. We also tested the association between
the variants and MDD in the GS:SFHS, UK Biobank and ELSA
(Supplementary Materials). If the variant was not available in a data set,
that data set was either removed or the variant in highest LD available in
both data sets was used. The constraint of the intercept at zero in IVW,
however, assumes that all IVs are valid. As this is not always the case, if a
signiﬁcant association (Po0.05) was indicated in IVW analysis, sensitivity
analysis with MR-Egger regression was conducted. As MR-Egger regression
does not constrain the intercept, it is therefore is not biased by invalid
IVs.38 The same effect beta’s and standard errors were utilised in the
MR-Egger regression. For further details on the methodology see
Supplementary Materials.
BUHMBOX
To further explore correlation between subcortical volume and MDD, we
utilised the technique BUHMBOX.22 This technique tests for the presence
of true pleiotropy and genetic subgroup heterogeneity within cases of a
disease phenotype (phenotype A) by measuring pairwise correlations of
risk alleles with another trait (phenotype B). The presence of phenotype B
risk alleles across all phenotype A cases and not phenotype A controls
provides evidence of true pleiotropy, whereas subgroup heterogeneity is
implicated if phenotype B risk alleles are enriched in a subgroup of
phenotype A cases. Pairwise correlations are combined to generate a
BUHMBOX test statistic for clinical heterogeneity. In this study, if a
signiﬁcant genetic correlation (Po0.05) was found, we utilised BUHMBOX
to further dissect the genetic relationship between regional brain volume
and MDD. We examined risk alleles associated with the ENIGMA regional
brain volumes as phenotype B with MDD phenotypes in GS:SFHS, UK
Biobank and ELSA as phenotype A. In order to minimise bias caused by
related individuals in GS:SFHS, an unrelated subsample was used
comprising 5659 individuals (786 MDD cases). LD pruning was conducted
using PLINK 1.9039 using --indep-pairwaise with r240.1 and a window size
of 50 SNPs and a sliding winding of ﬁve SNPs. The ﬁrst 4 PCs were ﬁtted in
GS:SFHS and ELSA and the ﬁrst 15 PCs were ﬁtted in UK Biobank to
account for additional heterogeneity.
Power Analyses
Power analyses for the genetic correlations (rG), calculated using LD score
regression, were completed using the GCTA-GREML power calculator.40 As
LD score regression utilises summary statistics and GCTA, the individual
genotype data, true power is likely to be slightly lower; however, the GCTA-
GREML power calculator gives a close estimate. Results of the power
analysis are presented in Supplementary Table S1.
Simulations of genetic correlations varying from 0.1 to 0.5 between the
brain volume and MDD indicated that, at rG = 0.5, we had power to detect
an association (Po0.05) in all regions. However, genetic correlation was
found to be much lower for many of the regions and therefore we only
had adequate power to detect a correlation between hippocampal volume
and MDD (power = 93%). For the remaining regions, a power curve was
conducted to demonstrate the size of the sample needed for sufﬁcient
power (Figure 1 and Supplementary Figure S2). Results indicate that an
additional ~ 15 000 sample increase in both ENIGMA and PGC samples
would be needed to detect signiﬁcant genetic correlations between MDD
and either putamen or ICV at the estimates reported in this analysis. To
demonstrate signiﬁcant genetic correlation between MDD and either
nucleus accumbens or pallidum volumes would require sample size
increases of greater than 100 000 in both samples. Power curves of
simulated genetic correlations (varying from 0.1 to 0.5) were also
constructed to identify the genetic correlation that we would have had
power to detect at the current sample size. Results indicate that this
sample had adequate power to detect a genetic correlation of at least 0.24
for putamen, 0.26 for nucleus caudate, 0.33 for both pallidum and ICV, 0.37
for hippocampus, 0.38 for thalamus and 0.49 for nucleus accumbens.
Power analysis of PRS were completed using AVENGEME.41 Markers were
assumed to be independent and 5% of SNPs were assumed to have an
effect in the training sample. Genetic covariance values were taken from
the LD score regression analysis, however, no value could be computed for
amygdala therefore three hypothetical covariances were tested; 0.50, 0.25
and 0.10. Results of the power analysis are presented in Supplementary
Table S3.
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Figure 1. Power curves were calculated with starting point 0 as the sample size in our analysis. For the genetic correlation power analysis the
power curves demonstrate (a(i)) the sample size increase needed for detecting a signiﬁcant association at the estimates reported in this
analysis when both samples were increased equally and, for MDD, the proportion of cases and controls was kept constant and (a(ii)) the
genetic correlation that there would be power to detect at the sample size reported in this analysis. For PRS power analysis (b) the sample size
for the training set (ENIGMA) was kept constant while the target set sample size was increased. Amygdala was assumed to have a rG= 0.25 for
the PRS power analysis. Hippocampus had adequate power in the genetic correlation analysis and therefore was not included in the
power curve. ICV, intracranial volume; MDD, major depressive disorder; PRS, polygenic risk scoring.
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Despite a study size of 49 576 individuals, PRS was under-powered in all
analyses. Highest power in the meta-analyses was for hippocampal
volumes (37%). Low SNP heritability and low covariance between traits
account for the low power in the meta-analyses. In the PRS analysis on
their own trait, highest powered was the putamen (23%) at a P-value
threshold of 1. In this analysis a small sample size of 968 individuals likely
reduced power. We therefore conducted a power curve for both the meta-
analysis and PRS in their own trait to indicate the sample size that would
be necessary to have adequate power (Figure 1 and Supplementary
Figure S3). Power curves indicate that a sample increase of ~ 100 000
individuals in the target set would be sufﬁcient power for hippocampus
PRS associated with MDD, however nearly 900 000 for amygdala assuming
a covariance of 0.25 and an increase of over 1 million participants for
nucleus accumbens, pallidum and thalamus.
RESULTS
Genetic correlation
Using LD score regression, we calculated SNP-based heritability
estimates for the seven subcortical regions and ICV with MDD,
utilising summary data from GWAS completed by ENIGMA17 and
PGC,33 respectively. The estimate of the SNP heritability for the
amygdala was non-signiﬁcant and therefore the amygdala was
not included in any further analysis. SNP heritability estimates for
the remaining subcortical volumes ranged from the SNP
h2 = 0.0855 (s.e. = 0.0438) for the nucleus accumbens to SNP
h2 = 0.297 (s.e. = 0.051) for the putamen (Table 1). MDD SNP
heritability was calculated at 0.204 (s.e. = 0.0386). Genetic correla-
tion between each subcortical region and ICV with MDD was then
calculated. Hippocampal volume demonstrated signiﬁcant genetic
correlation with MDD (rG = 0.460, s.e. = 0.200, P= 0.0213; Table 1),
although this did not survive multiple testing correction using
false discovery rate adjustment (Supplementary Table S3). No
other subcortical volume or ICV was genetically correlated
with MDD.
Polygenic risk score
Association between regional brain volume PRS and its respective
volume. Subcortical and ICV PRS were calculated in UK Biobank
to examine the association between each regional volume PRS
and its own volume. PRS were positively associated with their
respective volume in four of the eight structures across the ﬁve P-
value thresholds; caudate nucleus, ICV, putamen and thalamus. In
addition, hippocampus was signiﬁcantly associated at a P-value
threshold of 0.01 only. These results retained signiﬁcance after
multiple test correction across the ﬁve thresholds, however only
raw P-values have been reported. Nucleus accumbens, amygdala
and pallidum PRS did not demonstrate any association with their
respective volume. The variance explained by PRS was small for all
volumes, with the largest reported in the caudate nucleus
(R2 = 0.0102, β= 0.117, P= 1.08 × 10− 4; Figure 2 and
Supplementary Table S2).
Association between regional brain volume PRS and MDD. Struc-
tural PRS were selected at the threshold that best predicted its
own volume (nucleus accumbens = 0.01, amygdala = 0.1, caudate
nucleus = 0.5, hippocampus = 0.01, ICV = 0.5, pallidum=0.5, puta-
men= 0.1, thalamus = 0.05) and tested for prediction of MDD
status. No PRS for any volume was signiﬁcantly associated with
MDD status in any of the cohorts (Supplementary Table S4). In
Table 1. SNP-based heritability (h2) and genetic correlation (rG) of subcortical brain regions and ICV with MDD
SNP heritability Genetic correlation with MDD
Brain region SNP h2 s.e. Z-score rG s.e. Z-score P
Nucleus accumbens 0.0855 0.0438 1.95 0.0458 0.210 0.218 0.828
Caudate nucleus 0.253 0.0432 5.86 0.0752 0.130 0.580 0.562
Hippocampus 0.137 0.0481 2.85 0.460 0.200 2.30 0.0213
ICV 0.167 0.0462 3.61 0.123 0.166 0.739 0.460
Pallidum 0.171 0.049 3.49 − 0.0077 0.158 − 0.0491 0.961
Putamen 0.297 0.051 5.82 0.0986 0.118 0.834 0.404
Thalamus 0.125 0.0401 3.12 − 0.0808 0.177 − 0.457 0.648
Abbreviations: ICV, intracranial volume; MDD, major depressive disorder; SNP, single-nucleotide polymorphism. The heritability of amygdala was nonsigniﬁcant
and therefore removed from subsequent analysis. The P-values shown are uncorrected for multiple testing (for the results corrected for multiple testing see
Supplementary Table S2).
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Figure 2. Signiﬁcant P-values (o0.05) are indicated with asterisk (*). Nucleus accumbens, amygdala and pallidum PRS were not signiﬁcantly
associated with their respective volume at any threshold. ICV, intracranial volume; PRS, polygenic risk scoring.
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order to increase power, we completed a meta-analysis of the
summary association statistics from three cohorts. No evidence of
heterogeneity was identiﬁed in any of the meta-analyses. We
found no association between any structural PRS and MDD
(Figure 3a and Supplementary Figure S4).
Association between hippocampus volume PRS and MDD traits.
Association between hippocampal volume and recurrent MDD
and early illness onset has been previously reported.5,36 We
therefore examined MDD phenotypes in association with hippo-
campal volume PRS in GS:SFHS and UK Biobank, these data were
not available for the ELSA cohort. There was no association
between hippocampal PRS and recurrent MDD (OR= 0.98,
P= 0.0850) (Figure 3b). Further, hippocampal volume PRS was
not signiﬁcantly associated with number of episodes (β=
− 0.00390, P= 0.425), MDD duration (β=− 0.00110, P= 0.414) or
age of onset (β= 0.0142, P= 0.291; Supplementary Figure S5).
Mendelian randomisation
To further examine the nominally signiﬁcant genetic correlation
between hippocampus and MDD, MR analysis was performed to
test for a directional association between hippocampal volume
and MDD. Only two genome-wide signiﬁcant variants were
identiﬁed in the original ENIGMA GWAS (rs61921502 and
rs77956314) and these SNPs were only present in two of the
cohorts (GS:SFHS and UK Biobank). To obtain a value for variant—
outcome in the PGC data set, we selected the SNPs in highest LD
with the two causal variants that were available in both ENGIMA
and PGC summary statistics; rs17765551 and rs7294919. We also
conducted the analysis using values obtained with the causal
variants from meta-analysis with GS:SFHS and UK Biobank. IVW
analysis did not identify evidence for a causal association between
hippocampus variants and MDD in using either PGC MDD as the
outcome nor GS:SFHS and UK Biobank MDD (Supplementary Table
S5), it was therefore not necessary to carry this forward into the
MR-Egger regression model.
BUHMBOX
To further investigate whether the genetic correlation found
between hippocampus volume and MDD could be due to genetic
subgroup heterogeneity, we utilised the software package
BUHMBOX. SNP subsets were used that were associated with
hippocampal volume at a threshold of Po1.0 × 10− 3 and had to
be present in all individuals per cohort therefore 388, 504 and 386
SNPs, and 5659, 7017 and 4118 individuals remained in GS:SFHS,
UK Biobank and ELSA, respectively. Clinical heterogeneity was
found in GS:SFHS MDD cases (Z-score = 2.78, P= 0.00281), demon-
strating excessive pairwise correlations between risk alleles for
hippocampus volume and a subgroup of MDD cases. This survived
false discovery rate multiple testing correction, however, this
ﬁnding was not replicated in either UK Biobank or ELSA (Table 2).
DISCUSSION
Previous studies have reported phenotypic associations between
brain volumes and MDD. In this study, we investigated whether
there was evidence of shared genetic architecture between
subcortical brain volumes and ICV with MDD. Results from the
genetic correlation analysis indicate that hippocampal volume and
MDD are partially inﬂuenced by common genetic variants
(rG = 0.46, s.e. = 0.200, P= 0.0213), although this did not survive
correction for multiple testing. This positive genetic correlation is
novel, so far as any of the authors are aware, however Mathias
et al.42 demonstrated signiﬁcant negative correlation between
recurrent MDD and right hippocampal volume measured via
linkage analysis in a sample of 893 individuals. No other brain
regions’ volume showed evidence of shared genetically aetiology
with MDD. Our sample size was adequate to detect a correlation at
rG = 0.5, however, at the values reported in this study, we were
underpowered in all other brain volumes (excluding hippocam-
pus). Power analyses indicate that we had insufﬁcient power to
detect weak to modest genetic correlations in this study. Although
we were able to demonstrate lack of strong genetic correlations
between regional brain volumes (excepting hippocampus) and
Figure 3. Both plots demonstrate a negative correlation with MDD and recurrent MDD with no heterogeneity between cohorts but neither
plot reaches statistical signiﬁcance. CI, conﬁdence intervals; GS:SFHS, Generation Scotland: Scottish Family Health Study; MDD, major
depressive disorder; OR, odds ratio; seTE, standard errors; TE, treatment effect (regression beta’s); W(ﬁxed), weight of individual studies in ﬁxed
effect meta-analysis.
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MDD, we cannot with conﬁdence exclude the possibility that
they are weakly to modestly correlated. Therefore, further
analysis utilising larger sample sizes (a minimum of 15 000
increase in both samples) would be necessary to draw con-
ﬁrmatory conclusions.
Brain volume PRS were not associated with their own volume in
three out of the eight structures and was only associated with
hippocampal volume at P-value threshold 0.01. This is likely due to
the analysis being underpowered to detect an association in a
sample size of 968 participants. Of the PRS that were associated
with their phenotype, the largest proportion of variance explained
was 1% with the majority predicting ~ 0.6%. The proportion of
variance explained is therefore very low although this is fairly
common in PRS studies43 with one of the largest explained
variance by PRS reported in schizophrenia (~7% on the liability
scale).44
Meta-analysis of data from three studies, totalling 49 576
individuals including 11 552 cases, found no evidence of
association between any regional brain volume PRS and MDD,
including the hippocampus. As previous neuroimaging evidence
suggests that decreased hippocampal volumes could occur as a
cause or consequence of recurrent depressive episodes and early
illness onset,5,36 we examined hippocampal volume PRS associa-
tions with recurrent MDD, number of episodes, MDD duration and
age of onset but we observed no signiﬁcant associations. Despite
the PRS meta-analysis being the largest analysis to date examining
genetic scores for brain volume and MDD, it was severely
underpowered; therefore, we can draw no conﬁrmatory conclu-
sions about the genetic overlap between any structure and MDD
from this analysis. The apparent discrepancy between PRS and our
ﬁnding LD score regression is likely due to this lack of power,
however, as LD information is utilised in LD score regression and
SNPs are pruned in PRS calculation, it is also possible that the ‘loss
of information’ involved in calculating PRS contributed. Previous
simulation studies have demonstrated that predictive capabilities
of PRS are greatly enhanced when utilising LD information.45 This
implies that LD pruning may be removing causal SNPs and those
more closely tagging causal variants, resulting in a loss of
information and predictive accuracy.
To further dissect the positive genetic correlation between
hippocampus and MDD, we utilised MR and BUHMBOX techni-
ques. MR was used to determine the causality of genetic variants
in association with hippocampal volume and MDD. We did not
detect a causal association, however, there were only two
genome-wide signiﬁcant SNPs associated with hippocampal
volume in the original GWAS. Larger numbers of associated
variants increase power in MR analysis38 therefore this was likely a
contributing factor in this analysis. We also applied BUHMBOX
to investigate genetic subgroup heterogeneity and detected
evidence of a subgroup in MDD cases within GS:SFHS. We
did not replicate this ﬁnding in UK Biobank or ELSA, however,
MDD cases are not deﬁned using a clinical measure in these
cohorts, whereas GS:SFHS cases are deﬁned using DSM-IV criteria.
The PGC MDD deﬁnition also most closely matches that of GS:
SFHS MDD, although the GS:SFHS sample was population-based
rather than identiﬁed from a clinically ascertained samples.
This could explain why the ﬁndings were associated with these
cohorts and not the others. The observed lack of replication may
then be due to factors related to ascertainment differences and
should therefore be replicated in a clinically determined MDD
sample.
We conclude that hippocampal volume and MDD may share
common genetic factors, although this result did not withstand
multiple testing correction. Animal models have previously
demonstrated that increased stress can drive decreased hippo-
campal neurogenesis (and therefore increased atrophy)46 and this
reduced neurogenesis can lead to depressive-like symptoms.47
Stress is a well-established environmental risk factor associated
with MDD48 and the inhibition of glucocorticoid receptors has
been shown to normalise hippocampal neurogenesis49 and relieve
symptoms in psychotic major depression.50 Furthermore,
increased duration of depression has also been related to more
pronounced hippocampal reductions.51 Our results however
indicated a positive genetic correlation suggesting that genetic
variants determining larger hippocampal volume may be risk
factors for MDD. The clinical heterogeneity found utilising
BUHMBOX in GS:SFHS could provide a possible explanation for
the deviation from literature. If genes for larger hippocampal
volume are present in a subgroup of MDD only, then it is possible
that hippocampal volume atrophy could be associated with a
different subgroup of individuals that are affected through more
environmental pathways. Hippocampal volume has been demon-
strated to be more highly impacted by the environment than
other brain regions52 and is associated with many environmental
factors, for example, stress,48 increased exercise training53 and jet
lag.54 It is therefore possible that the previously reported
decreased hippocampal volume associated with MDD is due to
multiple episodes of depression and that this positive genetic
correlation is due to a role in MDD susceptibility earlier in brain
development. In fact, it has been previously demonstrated that
ﬁrst episode MDD subjects exhibited marginally larger hippocam-
pal volumes in comparison to healthy controls.55 This could also
provide explanation for the opposing negative genetic correlation
ﬁnding by Mathias et al.42 as they examined recurrent MDD.
However, it should be noted that this study did not demonstrate
signiﬁcant hippocampal atrophy in analysis including controls,55
which has been similarly shown in another study.56 Given that this
positive correlation could be associated with a subgroup of MDD
cases, it is also possible that this is hindering investigations into
hippocampus and all MDD cases. Hippocampal volume changes
are also widely associated with other psychiatric disorders such as
schizophrenia. A similar analysis that examined the genetic
correlation between subcortical volumes and schizophrenia found
no signiﬁcant correlations.57 This is suggestive that the genetic
correlation observed could be speciﬁc to hippocampal volume in
MDD. However, these results are only indicative of a genetic
correlation between the two traits and further research would be
necessary to provide conﬁrmative evidence.
A number of limitations of this study should be noted; ﬁrst, this
study only explored the effects of common genetic variants and it
Table 2. BUHMBOX results for hippocampus volume and MDD in GS:SFHS, ELSA and UK Biobank
BUHMBOX P Pcorrected Z-score N Cases Controls SNPs N Pleiotropy P Pleiotropy β Pleiotropy s.e.
GS:SFHS 0.00281 0.00843 2.77 5659 786 4873 388 0.0890 − 0.0448 0.0263
UK Biobank 0.893 0.893 − 1.24 7017 2316 4701 504 0.926 − 0.00128 0.0138
ELSA 0.678 0.893 −0.462 4116 544 3572 386 0.650 0.0144 0.0316
Abbreviations: GS:SFHS, Generation Scotland: Scottish Family Health Study; ELSA, English Longitudinal Study of Ageing. Signiﬁcant results (Po0.05) are shown
in bold.
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may be important to examine rarer variants to generate a more
complete picture, although this will require larger sample sizes.
Second, the lower heritability, higher prevalence and likely
heterogeneity of MDD results in less precise estimates of marker
weights from GWAS,58 decreasing the power to detect genetic
correlations with other phenotypes. Power of the PRS is limited
also by the size of the initial ENIGMA GWAS (n= 11 840), larger
discovery sample sizes greatly improve the accuracy of PRS.44,59
Therefore, larger genome-wide analysis would be necessary to
generate conﬁrmatory conclusions. Third, the estimates for SNP
heritability, calculated using LD score regression, were lower than
have been previously described.60 LD score regression has been
utilised previously to calculate SNP heritability of subcortical
volumes using the ENIGMA summary data with similar low
estimates reported.57
Despite these limitations, we provide some evidence of a
positive genetic correlation between hippocampal volume and
MDD and an indication of MDD subgroup heterogeneity, however,
the genetic correlation did not survive multiple testing correction
and the subgroup heterogeneity was not replicated. We did not
demonstrate an association utilising PRS techniques, however, low
power, low explanation of variance and loss of LD information
were notable limitations. Although we demonstrate a potential
genetic relationship between hippocampal volume and MDD in a
subgroup of individuals, we believe one of the most important
outcomes for the current study is in the planning for future
studies. Sample sizes of ~ 150 000 individuals will be needed to
have sufﬁcient statistical power (40.8) to detect shared genetic
architecture between MDD and hippocampal volume using PRS,
using data sets similar to the one studied. The other regional brain
volumes ranged from needing an additional sample size of
~ 400 000 to in excess of 1 million individuals. Alternatively, further
studies may utilise data from further releases of the ENIGMA
consortium, including larger numbers of participants and more
accurately determined SNP effect sizes. Further research into
subgrouping in the association between hippocampus and MDD
may also be beneﬁcial.
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